Brinton Pharmaceuticals raises $8 million from India Alternatives Investment Advisors

Brinton is now aiming for a leadership position in its represented product markets, having recently expanded into the paediatric dermatology and respiratory segments.
Brinton Pharmaceuticals raises $8 million from India Alternatives Investment Advisors
Brinton Pharmaceuticals raises $8 million from India Alternatives Investment Advisors
Written by:

Brinton Pharmaceuticals Limited, an Indian pharmaceutical company focused on dermatology has raised $8 million from India Alternatives Investment Advisors for a significant minority stake. Brinton also recently expanded into the paediatric dermatology and respiratory segments.

“We are excited to partner with an investor of the calibre of India Alternatives and strongly believe this association will bring synergies and help us continue our profitable growth journey. This investment will enhance our capabilities in formulations and Research & Development for niche areas of dermatology and cosmetology and support expansion of the company’s footprint within India as well as globally,” Rahulkumar Darda, Chairman & Managing Director, Brinton Pharmaceuticals said in a statement.  

Established in 2013, Brinton Pharmaceuticals is a speciality-focused pharmaceuticals company offering a range of branded dermatology and paediatric formulations. Through a specialized and dedicated field force of over 500 personnel, the company’s products are marketed in India and in 12 countries across emerging markets.

Commenting on the investment, Shivani Bhasin Sachdeva, Founder and CEO, India Alternatives said, “India Alternatives’ investment in Brinton reflects its recognition of the Company’s solid management team, differentiated brands and focus on niche therapeutic segments. The investment in Brinton fits very well with two of our themes of women oriented consumption and health & wellness. We are excited to partner with Rahul and his team to support them through the next leg of their journey.” This transaction marks the second investment in Brinton by an institutional investor, following Tata Capital Healthcare Fund’s investment in 2017. Equirus Capital Private Limited acted as exclusive financial advisor to Brinton Pharmaceuticals, PDS Legal and Transaction Square acted as legal and tax advisors respectively to Brinton Pharmaceuticals. DSK Legal acted as legal advisors to India Alternatives.

Vijey Christopher J, Director, Brinton Pharmaceuticals adds that the company is now aiming for a leadership position in its represented product markets and has a strategic road-map to cross several milestones in the coming years.

Related Stories

No stories found.
The News Minute
www.thenewsminute.com